Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.49 |
| ▸ | NPC1 | O15118 | 10/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.49 |
| ▸ | IL6 | P05231 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 10/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.48 |
| ▸ | RELA | Q04206 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GRK6 | P43250 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028457 | 0.81 | RAB9A (0.59) | RAB9ANPC1RXFP1GFERMEN1 | |
| SCHEMBL21979448 | 0.78 | HDAC6 (0.48) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL3746183 | 0.78 | RAB9A (0.43) | RAB9ANPC1RXFP1GFERIL6 | |
| SCHEMBL3750081 | 0.77 | RAB9A (0.48) | RAB9ANPC1RXFP1GFERIL6 | |
| SCHEMBL2245521 | 0.77 | RAB9A (0.73) | RAB9ANPC1RXFP1GFERMEN1 | |
| SCHEMBL8898712 | 0.76 | ELANE (0.61) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL11856050 | 0.76 | CYP1A2 (0.56) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL18344160 | 0.76 | HDAC6 (0.49) | RAB9ANPC1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL3753685 | 0.76 | RAB9A (0.47) | RAB9ANPC1RXFP1GFERIL6 | |
| SCHEMBL13054198 | 0.75 | RAB9A (0.46) | RAB9ANPC1RXFP1GFERIL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | claimed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | claimed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | claimed |
| US-10584118-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-10 | — | — | US | claimed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | claimed |
| EP-3310767-A1 | NADPH OXIDASE 4 INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2018-04-25 | — | — | EP | claimed |
| WO-2016207785-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-29 | — | — | WO | claimed |
| CN-107743483-B | NADPH oxidase 4 inhibitors | 埃科特莱茵药品有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELTION PHARMACEUTICALS LTD (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2021-10-05 | — | — | US | disclosed |
| EP-3310767-B1 | 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-07-22 | — | — | EP | disclosed |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-05-28 | — | — | US | disclosed |
| US-10584118-B2 | NADPH oxidase 4 inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-10 | — | — | US | disclosed |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-06-28 | — | — | US | disclosed |
| EP-3310767-A1 | NADPH OXIDASE 4 INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016207785-A1 | NADPH OXIDASE 4 INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584118-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | RAB9A 2128/4885NPC1 3120/4885RXFP1 1494/4885 |
| US-20200165235-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | RAB9A 2128/4885NPC1 3120/4885RXFP1 1494/4885 |
| US-11136317-B2 | NADPH oxidase 4 inhibitors | NOX4, NOX1, CYBB | RAB9A 2128/4885NPC1 3120/4885RXFP1 1494/4885 |
| US-20180179194-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | RAB9A 2128/4885NPC1 3120/4885RXFP1 1494/4885 |
| US-20210395238-A1 | NADPH OXIDASE 4 INHIBITORS | NOX4, NOX1, CYBB | RAB9A 2128/4885NPC1 3120/4885RXFP1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.